AAOI
Applied Optoelectronics, Inc.
AAOI has the edge over ICHR overall, supported by stronger valuation and stronger modeled upside.
ICHR
Ichor Holdings, Ltd.
ICHR has lower modeled downside risk, despite its lower overall score.
AAOI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
AAOI's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
ICHR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Weak | |
| Strong |
ICHR's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
AAOI PE Valuation
AAOI has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 18x next year's earnings.
ICHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $37.07 | — |
| Cheap | 13x | $0.63 | -98% |
| Fair | 20x | $1.01 | -97% |
| Expensive | 42x | $2.11 | -94% |
| Current | 741x | $37.07 | — |
Historical ranges are pointers, not guarantees.
ICHR's PE is in its expensive range at 741x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
AAOI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect AAOI to return to profit, with revenue growing. However, they disagree widely on these estimates.
ICHR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for ICHR, with profitability improving.
AAOI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.98 | — |
| Q3 2026 | -$0.42 | +$3.02 |
| Q2 2026 | -$0.77 | +$2.81 |
| Q1 2026 | -$0.65 | +$3.43 |
| Q4 2025 | -$0.64 | +$3.86 |
| Q3 2025 | -$3.44 | -$1.41 |
| Q2 2025 | -$3.58 | -$1.70 |
| Q1 2025 | -$4.08 | -$2.29 |
| Q4 2024 | -$4.50 | -$2.75 |
AAOI is still losing money, but far less than before: $0.42 per share over the past year, against $4.50 at its worst in late 2024.
ICHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.17 | +6237% |
| Q3 2026 | $0.05 | +$1.24 |
| Q2 2026 | -$1.17 | -$0.57 |
| Q1 2026 | -$1.48 | -$1.01 |
| Q4 2025 | -$1.54 | -$0.90 |
| Q3 2025 | -$1.19 | -$0.26 |
| Q2 2025 | -$0.60 | +$0.61 |
| Q1 2025 | -$0.47 | +$1.30 |
| Q4 2024 | -$0.64 | +$0.83 |
ICHR has the edge over AAOI on earnings quality, reporting a profit while its opponent remains loss making.
AAOI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $269.9M | +127% |
| Q2 2026 | $191.9M | +86% |
| Q1 2026 | $151.1M | +51% |
| Q4 2025 | $134.3M | +34% |
| Q3 2025 | $118.6M | +82% |
| Q2 2025 | $103M | +138% |
| Q1 2025 | $99.9M | +146% |
| Q4 2024 | $100.3M | +66% |
AAOI has the edge over ICHR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.5% | +15 points |
| Q2 2026 | -13% | +2.6 points |
| Q1 2026 | -8.6% | +0.3 points |
| Q4 2025 | -8.6% | -2.1 points |
| Q3 2025 | -15% | +10 points |
| Q2 2025 | -16% | +45 points |
| Q1 2025 | -8.9% | +44 points |
| Q4 2024 | -6.5% | +1 points |
AAOI's operating margin was −0.5% last quarter, up 15 points from the same quarter a year ago, near the top of its range since 2019.
ICHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $328.7M | +37% |
| Q2 2026 | $294.8M | +23% |
| Q1 2026 | $256.1M | +4.7% |
| Q4 2025 | $223.6M | -4.2% |
| Q3 2025 | $239.3M | +13% |
| Q2 2025 | $240.3M | +18% |
| Q1 2025 | $244.5M | +21% |
| Q4 2024 | $233.3M | +15% |
ICHR's revenue is growing: $329M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.9% | +15 points |
| Q2 2026 | 2.4% | +4.4 points |
| Q1 2026 | 0.8% | +1.3 points |
| Q4 2025 | -6.2% | -5.7 points |
| Q3 2025 | -8.1% | -7.9 points |
| Q2 2025 | -2% | -0.9 points |
| Q1 2025 | -0.5% | +1.4 points |
| Q4 2024 | -0.5% | +3.4 points |
ICHR has the edge over AAOI on profitability, with a higher operating margin.
AAOI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$369.9M | -$291.2M |
| Q2 2026 | -$265.3M | -$174.4M |
| Q1 2026 | -$143.6M | -$64.3M |
| Q4 2025 | -$104.6M | -$51.6M |
| Q3 2025 | -$78.7M | -$58M |
| Q2 2025 | -$91M | -$86M |
| Q1 2025 | -$79.3M | -$45.1M |
| Q4 2024 | -$53M | -$48.4M |
AAOI has burned cash in almost every quarter: −$883M over the past year, against −$302M the year before.
ICHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.5M | -1983% |
| Q2 2026 | -$23.6M | -$8.8M |
| Q1 2026 | -$10M | -2113% |
| Q4 2025 | $5.9M | +$12.8M |
| Q3 2025 | $2.1M | -3.3% |
| Q2 2025 | -$14.8M | -201% |
| Q1 2025 | $496K | +58% |
| Q4 2024 | -$6.9M | -119% |
ICHR has the edge over AAOI on cash flow, with more consistent year-over-year improvement.
AAOI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.7% | +6.3M shares |
| 1 year | +39% | +24.5M shares |
| 3 years | +168% | +55.1M shares |
| 5 years | +224% | +60.7M shares |
| Available history | +340% | +67.9M shares |
AAOI has 88M diluted shares, up 39% from a year ago.
ICHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.1% | +1.9M shares |
| 1 year | +11% | +3.8M shares |
| 3 years | +30% | +8.9M shares |
| 5 years | +31% | +9.1M shares |
| Available history | +67% | +15.4M shares |
ICHR has the edge over AAOI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
AAOI Net Leverage
AAOI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ICHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.9x | Net Cash |
| Q2 2026 | -16.3x | Net Cash |
| Q3 2025 | 6.5x | High |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.9x | Very low |
| Q3 2024 | 0.8x | Very low |
| Q2 2024 | 1.1x | Healthy |
ICHR has more cash than debt.
AAOI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.1 | Neutral |
| Stochastic | 4.8 | Oversold |
AAOI's weekly RSI is 35 (neutral) and its Stochastic is 5 (oversold).
ICHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 10.0 | Oversold |
ICHR's weekly RSI is 38 (neutral) and its Stochastic is 10 (oversold).
AAOI PE vs Technology Sector
AAOI has no meaningful PE right now: it lost money over the past year.
ICHR PE vs Technology Sector
| Metric | ICHR | Sector median | Relative |
|---|---|---|---|
| PE | 741x | 28x | 2,561% above |
| PE % | 100 | 35 | 65 pts above |
ICHR is trading at 741x earnings, a 2561% premium to the Technology sector's median of 28x.
AAOI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $80.2 | 34% below |
| 20 week MA | $100.6 | 47% below |
| 50 week MA | $100.3 | 47% below |
| 100 week MA | $62.3 | 15% below |
| 200 week MA | $36.9 | 43% above |
AAOI has fallen below most of its moving averages, though it's still 43% above its 200-week average.
ICHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.0 | 19% below |
| 20 week MA | $61.7 | 40% below |
| 50 week MA | $54.6 | 32% below |
| 100 week MA | $38.3 | 3.1% below |
| 200 week MA | $35.8 | 3.5% above |
ICHR has fallen below most of its moving averages, though it's still 3.5% above its 200-week average.
AAOI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.5 | $8.77 | -24% |
| 2021 | $8.77 | $5.64 | -36% |
| 2022 | $5.64 | $1.95 | -65% |
| 2023 | $1.95 | $19.3 | +891% |
| 2024 | $19.3 | $37.7 | +95% |
| 2025 | $37.7 | $37.2 | -1.5% |
| 2026 YTD | $37.2 | $52.9 | +42% |
AAOI's yearly returns have swung widely, from +891% in 2023 to −65% in 2022. It's up 42% so far in 2026.
ICHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.9 | $30.5 | -10% |
| 2021 | $30.5 | $45.5 | +49% |
| 2022 | $45.5 | $26.2 | -42% |
| 2023 | $26.2 | $33.6 | +28% |
| 2024 | $33.6 | $31.4 | -6.7% |
| 2025 | $31.4 | $19.0 | -40% |
| 2026 YTD | $19.0 | $37.1 | +96% |
ICHR has the edge over AAOI on returns for 2026, with the stronger performance.